Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled budesonide for early COVID-19 to prevent deterioration and hospitalisation
2020-001889-10Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of budesonide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoint: Hospitalisation or emergency department attendance related to COVID-19. Status: unknown.
02
Drugs
budesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001889-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001889-10.